Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, and The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Shandong University Qilu Hospital, Jinan, Shandong, China.
Department of Physiology & Pathophysiology, School of Basic Medicine, Shandong University, Jinan, Shandong, China.
J Am Coll Cardiol. 2017 Jun 20;69(24):2952-2966. doi: 10.1016/j.jacc.2017.04.041.
Traditional Chinese medicine (TCM) has more than 2,000 years of history and has gained widespread clinical applications. However, the explicit role of TCM in preventing and treating cardiovascular disease remains unclear due to a lack of sound scientific evidence. Currently available randomized controlled trials on TCM are flawed, with small sample sizes and diverse outcomes, making it difficult to draw definite conclusions about the actual benefits and harms of TCM. Here, we systematically assessed the efficacy and safety of TCM for cardiovascular disease, as well as the pharmacological effects of active TCM ingredients on the cardiovascular system and potential mechanisms. Results indicate that TCM might be used as a complementary and alternative approach to the primary and secondary prevention of cardiovascular disease. However, further rigorously designed randomized controlled trials are warranted to assess the effect of TCM on long-term hard endpoints in patients with cardiovascular disease.
中医药(TCM)已有 2000 多年的历史,已广泛应用于临床。然而,由于缺乏有力的科学证据,中医药在预防和治疗心血管疾病方面的明确作用仍不清楚。目前关于中医药的随机对照试验存在缺陷,样本量小,结局多样,难以得出关于中医药实际益处和危害的确切结论。在这里,我们系统地评估了中医药治疗心血管疾病的疗效和安全性,以及活性中药成分对心血管系统的药理作用和潜在机制。结果表明,中医药可能作为心血管疾病一级和二级预防的一种补充和替代方法。然而,仍需要进一步设计严格的随机对照试验来评估中医药对心血管疾病患者长期硬终点的影响。